DK0837672T3 - Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme - Google Patents

Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme

Info

Publication number
DK0837672T3
DK0837672T3 DK96924371T DK96924371T DK0837672T3 DK 0837672 T3 DK0837672 T3 DK 0837672T3 DK 96924371 T DK96924371 T DK 96924371T DK 96924371 T DK96924371 T DK 96924371T DK 0837672 T3 DK0837672 T3 DK 0837672T3
Authority
DK
Denmark
Prior art keywords
cell
mediated diseases
preparations
treating
methods
Prior art date
Application number
DK96924371T
Other languages
English (en)
Inventor
Dana Elias
Irun R Cohen
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0837672T3 publication Critical patent/DK0837672T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Marine Sciences & Fisheries (AREA)
DK96924371T 1995-07-05 1996-07-02 Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme DK0837672T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases
PCT/US1996/011373 WO1997002016A1 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases

Publications (1)

Publication Number Publication Date
DK0837672T3 true DK0837672T3 (da) 2004-03-22

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924371T DK0837672T3 (da) 1995-07-05 1996-07-02 Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme

Country Status (22)

Country Link
EP (1) EP0837672B9 (da)
JP (2) JP4357595B2 (da)
KR (1) KR100435040B1 (da)
CN (1) CN1102382C (da)
AT (1) ATE254451T1 (da)
AU (1) AU714970B2 (da)
CA (1) CA2226013C (da)
CZ (1) CZ298A3 (da)
DE (1) DE69630787T2 (da)
DK (1) DK0837672T3 (da)
ES (1) ES2211963T3 (da)
HR (1) HRP960315A2 (da)
HU (1) HU223081B1 (da)
IL (2) IL114458A0 (da)
MX (1) MX9800190A (da)
NO (1) NO320363B1 (da)
PT (1) PT837672E (da)
SI (1) SI0837672T1 (da)
UY (1) UY24275A1 (da)
WO (1) WO1997002016A1 (da)
YU (1) YU40796A (da)
ZA (1) ZA965666B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
AU2003230181A1 (en) 2002-05-21 2003-12-02 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
EP1687423A4 (en) * 2003-11-24 2007-04-18 Yeda Res & Dev HSP60 PEPTIDE FRAGMENT-ENCODING DNA VACCINES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
US9078843B2 (en) 2005-09-22 2015-07-14 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients

Also Published As

Publication number Publication date
AU714970B2 (en) 2000-01-13
IL122755A0 (en) 1998-08-16
KR100435040B1 (ko) 2004-08-18
CA2226013A1 (en) 1997-01-23
SI0837672T1 (en) 2004-04-30
NO980013D0 (no) 1998-01-02
CZ298A3 (cs) 1998-06-17
MX9800190A (es) 1998-04-30
JP4357595B2 (ja) 2009-11-04
CA2226013C (en) 2012-09-18
AU6484496A (en) 1997-02-05
EP0837672B9 (en) 2005-06-15
WO1997002016A1 (en) 1997-01-23
NO320363B1 (no) 2005-11-28
CN1102382C (zh) 2003-03-05
JPH11508899A (ja) 1999-08-03
IL122755A (en) 2004-07-25
ATE254451T1 (de) 2003-12-15
DE69630787T2 (de) 2004-10-07
ZA965666B (en) 1997-01-27
NO980013L (no) 1998-02-19
DE69630787D1 (de) 2003-12-24
HUP9802834A3 (en) 2001-08-28
IL114458A0 (en) 1995-11-27
JP2009242412A (ja) 2009-10-22
PT837672E (pt) 2004-03-31
CN1193907A (zh) 1998-09-23
YU40796A (sh) 1998-11-05
EP0837672B1 (en) 2003-11-19
EP0837672A1 (en) 1998-04-29
KR19990028738A (ko) 1999-04-15
HU223081B1 (hu) 2004-03-29
ES2211963T3 (es) 2004-07-16
UY24275A1 (es) 2000-12-29
HRP960315A2 (en) 1998-02-28
HUP9802834A2 (hu) 1999-03-29
EP0837672A4 (en) 1999-01-27

Similar Documents

Publication Publication Date Title
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
EP0751781A4 (en) METHOD FOR PREVENTING OR TREATING A DISEASE, CHARACTERIZED BY THE NEOPLASTIC CELLS EXPRESSING CD40
NO980013L (no) Preparater og fremgangsmåter for behandling av T-cellemedierte sykdommer
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ES2104565T3 (es) Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
PT782630E (pt) Gene da doenca poliquistica do rim
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
DK0959899T3 (da) LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation
HUP9901077A2 (hu) Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
SU644924A1 (ru) Армоопалубочный пакет
UA28518A (uk) Спосіб визначення алергену у хворих на лікарську хворобу
MX9800821A (es) Aislamiento y/o conservacion de celulas dentriticas para la inmunoterapia del cancer de la prostata.
HN1996000030A (es) Uso de una mezcla itraconazol-secnidazol para el tratamientode enfermedades infecciosas en el aparato reproductor femenino.